Modulation of cell-type plasticity in favour of a gene expression signature with reduced stemness, an impaired ability of cells to dedifferentiate, as well as tumours having a lower invasive potential, all make targeting SRSF1 a highly attractive option, and may complement current standard-of-care therapies. The gene discussed is SRSF1; the disease is neoplasm.